Lv5
892 积分 2023-10-17 加入
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
4天前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
4天前
已完结
Karnofsky performance status revisited: reliability, validity, and guidelines
3个月前
已完结
Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co-Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGFR2 Study
3个月前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
3个月前
已完结
Second-line tarlatamab improves OS in SCLC
4个月前
已完结
Inside the Mind of the DMC: A Review of Principles and Issues with Case Studies
4个月前
已完结
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
4个月前
已完结
Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC
4个月前
已关闭
Inside the Mind of the DMC: A Review of Principles and Issues with Case Studies
5个月前
已完结
皖公网安备34019202002308
